CGC Genomics is a technology company.
CGC Genomics has raised $2.0M across 1 funding round.
CGC Genomics has raised $2.0M in total across 1 funding round.
CGC Genomics Consults AG is a Basel, Switzerland-based health technology company founded in 2023 that develops Qnomx, an AI-powered platform for interpreting cancer genomic profiles from next-generation sequencing (NGS) data.[1][2][4] It serves oncologists, pathologists, and labs by translating complex genomic reports into clear, clinically actionable summaries in minutes, addressing gaps where half of oncologists lack full cancer genomics expertise and 80% struggle with results—reducing analysis time from hours, cutting costs, and minimizing errors while ensuring "human in the loop" oversight.[1][2] The company has raised €1.7 million (about $1.93 million) in seed funding as of April 2025 from investors like Heal Capital, JVH Ventures, better ventures, and Becker Ventures, achieving early traction through internal efficiency gains and pilots with Labor Becker and OnkoMedeor Group; it's pursuing regulatory approval under IVDR, MDR, and the European AI Act to become the first generative AI tool in cancer diagnostics.[2][4][5]
CGC Genomics emerged in 2023 from an interdisciplinary team spotting the unmet need for seamless cancer genomics interpretation amid rising NGS adoption.[1][2] Joerg Hoelzing, PhD, a purposeful executive with expertise in strategic leadership and business development, co-founded the startup alongside James Creeden, Co-CEO with over 20 years at Roche, including as Global Head of Medical Affairs at Foundation Medicine, bringing deep oncology, genomics, and regulatory knowledge.[1][2] The idea crystallized around bridging oncologists' expertise gaps, validated through market research, leading to Qnomx's development as a proprietary explainable AI platform; early internal use demonstrated major time savings, paving the way for external pilots and seed funding in 2025.[2]
(Note: A separate non-profit, the Cancer Genomics Consortium (CGC), founded in 2009, focuses on clinical standards and education but is unrelated to this for-profit tech firm.[3])
CGC Genomics rides the precision oncology wave, where NGS generates vast genomic data but interpretation lags, fueled by AI advancements in healthcare and regulatory pushes like the EU AI Act.[1][2] Timing aligns with exploding demand for actionable insights—global precision medicine markets grow amid cancer's rising burden—while market forces like lab digitization and cost pressures favor tools like Qnomx that democratize expertise.[2] It influences the ecosystem by setting standards for safe GenAI in diagnostics, fostering collaborations with labs and ventures like Heal Capital, and accelerating "genomics as a service" for underserved oncologists worldwide.[2]
CGC Genomics is poised to scale Qnomx post-seed with regulatory wins and pilot expansions, targeting broader EU lab adoption and U.S. entry amid AI-health convergence.[2][4] Trends like multimodal AI integration and real-world evidence from pilots will shape its path, potentially evolving it into a full precision oncology platform influencing treatment recommendations globally—transforming genomic data from overwhelming to everyday expert counsel, much like its founding promise to make interpretation "as seamless as conversing with an expert."[1]
CGC Genomics has raised $2.0M in total across 1 funding round.
CGC Genomics's investors include Better Ventures, Contrarian Ventures, Felix Jahn.
CGC Genomics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $2.0M Seed | Better Ventures, Contrarian Ventures, Felix Jahn |